Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials

  • Amgad N. Makaryus
  • Philippe Akhrass
  • Samy I. McFarlane
Article

Abstract

Metabolic syndrome represents a constellation of hypertension, abdominal obesity, impaired fasting glucose, and dyslipidemia, and it has been shown to be a risk factor for cardiovascular disease. The components of metabolic syndrome are rapidly emerging as epidemics of the twenty-first century, and reduction of these underlying causes, such as obesity, physical inactivity, and atherogenic diet, is first-line therapy. Treatment of hypertension and other cardiometabolic risk factors of the syndrome is also required. Evidence demonstrates a relationship between hypertension, type 2 diabetes mellitus, and several vascular and metabolic abnormalities that are components of metabolic syndrome. Hypertension associated with metabolic syndrome has pathophysiologic characteristics that provide clinical challenges as well as opportunities for successful therapeutic interventions. This article reviews the treatment of hypertension as a metabolic and vascular disease and also opens a new paradigm for the treatment of metabolic syndrome, which affects nearly one quarter of the world’s population.

References and Recommended Reading

  1. 1.
    Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [no authors listed]. JAMA 2001, 285:2486–2497.Google Scholar
  2. 2.
    Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998, 15:539–553.PubMedCrossRefGoogle Scholar
  3. 3.
    International Diabetes Foundation: IDF worldwide definition of the metabolic syndrome. Available at http://www.idf.org/home/index.cfm?unode=1120071E-AACE-41D2-9FA0-BAB6E25BA072. Accessed January 2009.
  4. 4.
    Eckel RH, Grundy SM, Zimmet PA: The metabolic syndrome. Lancet 2005, 365:1415–1428.PubMedCrossRefGoogle Scholar
  5. 5.
    Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359.PubMedCrossRefGoogle Scholar
  6. 6.
    Suzuki T, Homma S: Treatment of hypertension and other cardiovascular risk factors in patients with metabolic syndrome. Med Clin North Am 2007, 91:1211–1223.PubMedCrossRefGoogle Scholar
  7. 7.
    Lloyd-Jones D, Adams R, Carnethon M, et al.: Heart Disease and Stroke Statistics—2009 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 119:480–486. (Published erratum appears in Circulation 2009, 119:e182.)Google Scholar
  8. 8.
    Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.PubMedCrossRefGoogle Scholar
  9. 9.
    Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 2002, 288:2709–2716.PubMedCrossRefGoogle Scholar
  10. 10.
    Girman CJ, Rhodes T, Mercuri M, et al.: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93:136–141.PubMedCrossRefGoogle Scholar
  11. 11.
    Malik S, Wong ND, Franklin SS, et al.: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245–1250.PubMedCrossRefGoogle Scholar
  12. 12.
    Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.PubMedCrossRefGoogle Scholar
  13. 13.
    McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718.PubMedCrossRefGoogle Scholar
  14. 14.
    Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374–381.PubMedCrossRefGoogle Scholar
  15. 15.
    Mancia G, De Backer G, Dominiczak A, et al.: 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28:1462–1536.PubMedGoogle Scholar
  16. 16.
    Poirier P, Giles TD, Bray GA, et al.: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898–918.PubMedCrossRefGoogle Scholar
  17. 17.
    Mancia G, Bombelli M, Corrao G, et al.: Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007, 49:40–47.PubMedCrossRefGoogle Scholar
  18. 18.
    Schmidt MI, Duncan BB, Bang H, et al.: Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2005, 28:2013–2018.PubMedCrossRefGoogle Scholar
  19. 19.
    Vasan RS, Beiser A, Seshadri S, et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002, 287:1003–1010.PubMedCrossRefGoogle Scholar
  20. 20.
    Schillaci G, Pirro M, Vaudo G, et al.: Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005, 45:1978–1982.CrossRefGoogle Scholar
  21. 21.
    Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111:1805–1812.PubMedGoogle Scholar
  22. 22.
    Nesto R: C-reactive protein its role in inflammation type 2 diabetes cardiovascular disease the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004, 21:810–817.PubMedCrossRefGoogle Scholar
  23. 23.
    Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210–1214.PubMedCrossRefGoogle Scholar
  24. 24.
    Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716.PubMedCrossRefGoogle Scholar
  25. 25.
    Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427–2443.PubMedCrossRefGoogle Scholar
  26. 26.
    Olshansky SJ, Passaro DJ, Hershow RC, et al.: A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005, 352:1138–1145.PubMedCrossRefGoogle Scholar
  27. 27.
    Mancia G, Bousquet P, Elghozi JL, et al.: The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007, 25:909–920.PubMedCrossRefGoogle Scholar
  28. 28.
    Whaley-Connell A, Palmer J, Sowers JR: Risk stratification and treatment options for hypertensive patients with metabolic syndrome and prediabetes. Adv Studies Med 2005, 5:S1011–S1018.Google Scholar
  29. 29.
    Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344:3–10.PubMedCrossRefGoogle Scholar
  30. 30.
    Clinical guidelines on the identification evaluation treatment of overweight obesity in adults: the evidence report [no authors listed]. Obes Res 1998, 6(Suppl 2):51S–209S.Google Scholar
  31. 31.
    El-Atat F, Aneja A, Mcfarlane S, Sowers J: Obesity and hypertension. Endocrinol Metab Clin North Am 2003, 32:823–854.PubMedCrossRefGoogle Scholar
  32. 32.
    Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.PubMedCrossRefGoogle Scholar
  33. 33.
    Tight blood pressure control and risk of macrovascular and microvascular complications in yype 2 diabetes: UKPDS38. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:703–713.Google Scholar
  34. 34.
    Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. Kidney Int 2002, 61:1086–1097.PubMedCrossRefGoogle Scholar
  35. 35.
    Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(Suppl 2):B54–B64.PubMedGoogle Scholar
  36. 36.
    Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757–764.PubMedCrossRefGoogle Scholar
  37. 37.
    Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [no authors listed]. JAMA 1991, 265:3255–3264.Google Scholar
  38. 38.
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group [no authors listed]. JAMA 2002, 288:2981–2997.Google Scholar
  39. 39.
    Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:713–720.Google Scholar
  40. 40.
    Israili ZH, Lyoussi B, Hernández-Hernández R, Velasco M: Metabolic syndrome: treatment of hypertensive patients. Am J Ther 2007, 14:386–402.PubMedCrossRefGoogle Scholar
  41. 41.
    Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. Lancet 1999, 353:611–616.PubMedCrossRefGoogle Scholar
  42. 42.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.PubMedCrossRefGoogle Scholar
  43. 43.
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group [no authors listed]. JAMA 2002, 288:2981–2997.Google Scholar
  44. 44.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.PubMedCrossRefGoogle Scholar
  45. 45.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. Lancet 2000, 355:253–259.Google Scholar
  46. 46.
    Khan K, Govindarajan G, Whaley-Connell A, Sowers JR: Diabetic hypertension. Heart Fail Clin 2006, 2:25–36.PubMedCrossRefGoogle Scholar
  47. 47.
    Sowers JR, Reed J: 1999 Clinical advisory treatment of hypertension in diabetes. J Clin Hypertens (Greenwich) 2000, 2:132–133.Google Scholar
  48. 48.
    Larochelle P, Clack JM, Marbury TC, et al.: Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997, 80:1613–1615.PubMedCrossRefGoogle Scholar
  49. 49.
    Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.PubMedCrossRefGoogle Scholar
  50. 50.
    Kintscher U, Bramlage P, Paar WD, et al.: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007, 6:12.PubMedCrossRefGoogle Scholar
  51. 51.
    Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.PubMedCrossRefGoogle Scholar
  52. 52.
    Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.CrossRefGoogle Scholar
  53. 53.
    Whaley-Connell A, Sowers JR: Hypertension management in type 2 diabetes and the JNC VII. In Endocrinology and Metabolism Clinics of North America. Edited by Einhorn D, Rosenstock J. Philadelphia: WB Saunders Company; 2005:63–75.Google Scholar
  54. 54.
    Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759–766.PubMedCrossRefGoogle Scholar
  55. 55.
    Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781.PubMedCrossRefGoogle Scholar
  56. 56.
    Gerstein HC, Yusuf S, Holman R, et al.: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004, 47:1519–1527.PubMedCrossRefGoogle Scholar
  57. 57.
    Palaniappan L, Carnethon MR, Wang Y, et al.: Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004, 27:788–793.PubMedCrossRefGoogle Scholar
  58. 58.
    Kaiser T, Heise T, Nosek L, et al.: Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006, 24:1397–1403.PubMedCrossRefGoogle Scholar
  59. 59.
    Poole-Wilson PA, Swedberg K, Cleland JG, et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7–13.PubMedCrossRefGoogle Scholar
  60. 60.
    Pyorala K, Ballantyne CM, Gumbiner B, et al.: Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004, 27:1735–1740PubMedCrossRefGoogle Scholar
  61. 61.
    Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998, 98:2513–2519.PubMedGoogle Scholar
  62. 62.
    Armitage J, Collins R: Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials MRC/BHF Heart Protection Study. Heart 2000, 84:357–360.PubMedCrossRefGoogle Scholar
  63. 63.
    Ridker PM, Danielson E, Fonseca FA, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207.PubMedCrossRefGoogle Scholar
  64. 64.
    Van de Laar FA, Lucassen PL, Akkermans RP, et al.: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2006, 4:CD005061.Google Scholar
  65. 65.
    Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096–1105.PubMedCrossRefGoogle Scholar
  66. 66.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761–775.PubMedCrossRefGoogle Scholar
  67. 67.
    Scheen AJ, Finer N, Hollander P, et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 2006, 368:1160–1172.Google Scholar
  68. 68.
    Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints Outcomes (CRESCENDO). Available at http://clinicaltrials.gov/ct2/show/NCT00263042. Accessed January 5, 2009.

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Amgad N. Makaryus
    • 1
  • Philippe Akhrass
  • Samy I. McFarlane
  1. 1.Department of CardiologyNorth Shore University HospitalManhassetUSA

Personalised recommendations